Unidade Local De Saúde De Santa Maria, E.P.E.
- Address
- lock Available on a paid plan
Nutritional and Metabolic Diseases Research
At Unidade Local De Saúde De Santa Maria, E.P.E., the Pediatria department is involved in clinical research focused on Nutritional and Metabolic Diseases, with a strong emphasis on rare inherited conditions affecting metabolism.
- Studies centered on Arginase 1 deficiency (ARG1-D), a rare metabolic disorder that can disrupt the body’s ability to process arginine.
- Research evaluating a new therapy for young children, with attention to how treatment may influence plasma arginine concentrations.
- Pediatric trials designed to better understand treatment safety and potential clinical benefit in very early childhood.
This area of research at the Lisbon site supports efforts to improve care for children with rare metabolic diseases by testing whether emerging treatments can help manage the underlying biochemical imbalance.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 436 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 412 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 78 by active trials.
- 1Merck Sharp & Dohme LLC12active
lock +77 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC24trials
lock +48 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Unidade Local De Saúde De Santa Maria, E.P.E.
lock Showing 1 of 321 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 436 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 33 | Unknown | 2015-11-06 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.